Featured Research

from universities, journals, and other organizations

Scientists discover driving force behind prostate cancer

Date:
March 27, 2013
Source:
University of York
Summary:
Scientists have discovered the driving force behind the development of prostate cancer. Their research reveals the existence of a cancer inducing DNA re-alignment in stem cells taken from human prostate cancers.

Scientists have discovered the driving force behind the development of prostate cancer. Their research reveals the existence of a cancer inducing DNA re-alignment in stem cells taken from human prostate cancers.
Credit: Nenov Brothers / Fotolia

Scientists at the University of York have discovered the driving force behind the development of prostate cancer.

Their research, published in Nature Communications today and funded by the charity Yorkshire Cancer Research, reveals the existence of a cancer inducing DNA re-alignment in stem cells taken from human prostate cancers.

This opens the way to the development of drugs that target the stem cells, leading to more effective therapies that work against the root cause of the disease.

Professor Norman Maitland, Director of the YCR Cancer Research Unit, and his team in the University’s Department of Biology were the first to isolate prostate cancer stem cells in 2005. While other cancer cells can be killed by current therapies, stem cells are able to evade their effects, resulting in cancer recurrence. The team has since been exploring the exact molecular properties that allow these cells to spread, survive and resist aggressive treatments such as radiation and chemotherapy.

Professor Maitland said: “This discovery marks a fundamental shift in our understanding of how solid cancers start. It is believed that ‘root’ cancer cells arise from healthy stem cells going wrong – for example certain controls can be turned off which allow the cells to keep growing and invade surrounding tissue.

“In blood cancers such as leukaemia, DNA is rearranged during an event known as chromosomal translocation, which results in a mutant protein that drives cancer progression. Although similar rearrangements have recently been discovered in solid cancers, until now, they have not been considered as stem cell functions. Our work has challenged this idea.”

Professor Maitland’s team has found these genetic accidents in prostate cancer stem cells and has shown that they result in a specific cancer-associated gene within the cells called ERG being inappropriately activated. It is believed that this activation triggers the stem cells to renew more often.

Professor Maitland continued: “The cells become selfish by surviving outside normal controls that exist in the prostate and thrive at the expense of their neighbours, ensuring that the genetic accident becomes permanent and passed from generation to generation. This process appears to be essential for the initiation of prostate cancer.”

Yorkshire Cancer Research funded a 2.15m five year programme at the YCR Cancer Research Unit in August 2011 to allow scientists to continue their internationally-award winning research into prostate cancer.

Kathryn Scott, Head of Research Funding at the charity, said: “This exciting discovery is another step forward in our understanding of how prostate cancer begins. Professor Maitland has detected one of the earliest possible changes in the development of prostate cancer. The findings mean that new therapies can now be developed which specifically target the protein identified, killing the stem cells that remain after chemotherapy while leaving healthy cells untouched.”


Story Source:

The above story is based on materials provided by University of York. Note: Materials may be edited for content and length.


Journal Reference:

  1. Euan S. Polson, John L. Lewis, Hamza Celik, Vincent M. Mann, Michael J. Stower, Matthew S. Simms, Greta Rodrigues, Anne T. Collins, Norman J. Maitland. Monoallelic expression of TMPRSS2/ERG in prostate cancer stem cells. Nature Communications, 2013; 4: 1623 DOI: 10.1038/ncomms2627

Cite This Page:

University of York. "Scientists discover driving force behind prostate cancer." ScienceDaily. ScienceDaily, 27 March 2013. <www.sciencedaily.com/releases/2013/03/130327132441.htm>.
University of York. (2013, March 27). Scientists discover driving force behind prostate cancer. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2013/03/130327132441.htm
University of York. "Scientists discover driving force behind prostate cancer." ScienceDaily. www.sciencedaily.com/releases/2013/03/130327132441.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins